LivaNova (LIVN) to Release Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $354.3120 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

LivaNova Stock Up 0.8%

LIVN opened at $68.42 on Monday. The stock’s 50 day moving average price is $64.04 and its 200 day moving average price is $58.45. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The stock has a market cap of $3.74 billion, a P/E ratio of -17.10 and a beta of 0.97. LivaNova has a 12 month low of $32.48 and a 12 month high of $69.31.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research note on Friday, January 9th. Piper Sandler reiterated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a report on Thursday. Barclays raised their price objective on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research note on Friday, January 9th. Mizuho upped their target price on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Robert W. Baird set a $75.00 target price on LivaNova in a research note on Tuesday, December 16th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $71.11.

Institutional Investors Weigh In On LivaNova

Hedge funds have recently made changes to their positions in the company. UMB Bank n.a. grew its position in LivaNova by 22.6% during the 4th quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after purchasing an additional 179 shares in the last quarter. Parallel Advisors LLC raised its position in LivaNova by 28.8% during the fourth quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after buying an additional 283 shares during the period. California State Teachers Retirement System raised its position in LivaNova by 0.9% during the second quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock valued at $2,260,000 after buying an additional 458 shares during the period. EverSource Wealth Advisors LLC lifted its stake in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares in the last quarter. Finally, State of Wyoming purchased a new position in LivaNova during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.